WESPAC Advisors SoCal LLC Has $681,000 Position in Eli Lilly and Company (NYSE:LLY)

WESPAC Advisors SoCal LLC reduced its stake in shares of Eli Lilly and Company (NYSE:LLY) by 55.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 825 shares of the company’s stock after selling 1,035 shares during the quarter. WESPAC Advisors SoCal LLC’s holdings in Eli Lilly and Company were worth $681,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the stock. City National Bank of Florida MSD lifted its stake in Eli Lilly and Company by 12.7% in the 1st quarter. City National Bank of Florida MSD now owns 914 shares of the company’s stock valued at $755,000 after acquiring an additional 103 shares in the last quarter. Egerton Capital UK LLP lifted its stake in Eli Lilly and Company by 75.4% in the 1st quarter. Egerton Capital UK LLP now owns 492,808 shares of the company’s stock valued at $407,015,000 after acquiring an additional 211,827 shares in the last quarter. Roundview Capital LLC lifted its stake in Eli Lilly and Company by 7.0% in the 1st quarter. Roundview Capital LLC now owns 4,717 shares of the company’s stock valued at $3,896,000 after acquiring an additional 309 shares in the last quarter. Advisors Preferred LLC bought a new stake in Eli Lilly and Company in the 1st quarter valued at approximately $2,738,000. Finally, Richardson Financial Services Inc. lifted its stake in Eli Lilly and Company by 13.3% in the 1st quarter. Richardson Financial Services Inc. now owns 376 shares of the company’s stock valued at $311,000 after acquiring an additional 44 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Erste Group Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday, June 5th. Morgan Stanley restated an “overweight” rating and issued a $1,135.00 price target (up previously from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. Cantor Fitzgerald assumed coverage on Eli Lilly and Company in a research note on Tuesday, April 22nd. They issued an “overweight” rating and a $975.00 price target on the stock. UBS Group dropped their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating on the stock in a research note on Friday, May 2nd. Finally, The Goldman Sachs Group upgraded Eli Lilly and Company from a “neutral” rating to a “buy” rating and dropped their price target for the company from $892.00 to $888.00 in a research note on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,012.56.

Eli Lilly and Company Stock Up 1.9%

LLY stock opened at $776.47 on Wednesday. The company has a market cap of $735.89 billion, a PE ratio of 63.18, a price-to-earnings-growth ratio of 1.10 and a beta of 0.40. The business has a 50-day simple moving average of $767.03 and a 200 day simple moving average of $800.17. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The business had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. During the same quarter in the prior year, the firm earned $2.58 EPS. The business’s revenue was up 45.2% on a year-over-year basis. Sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.77%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 48.82%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.